JP4865702B2 - サイトカイン阻害剤 - Google Patents

サイトカイン阻害剤 Download PDF

Info

Publication number
JP4865702B2
JP4865702B2 JP2007511450A JP2007511450A JP4865702B2 JP 4865702 B2 JP4865702 B2 JP 4865702B2 JP 2007511450 A JP2007511450 A JP 2007511450A JP 2007511450 A JP2007511450 A JP 2007511450A JP 4865702 B2 JP4865702 B2 JP 4865702B2
Authority
JP
Japan
Prior art keywords
alkyl
methyl
optionally
alkoxy
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007511450A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007536231A5 (https=
JP2007536231A (ja
Inventor
デレク コーガン
ダニエル アール ゴールドバーグ
ミン ホン ハオ
ザオミン シオン
ロナルド エイ オングスト
エイミー エル デイヴィス
Original Assignee
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド filed Critical ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド
Publication of JP2007536231A publication Critical patent/JP2007536231A/ja
Publication of JP2007536231A5 publication Critical patent/JP2007536231A5/ja
Application granted granted Critical
Publication of JP4865702B2 publication Critical patent/JP4865702B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2007511450A 2004-05-03 2005-04-29 サイトカイン阻害剤 Expired - Fee Related JP4865702B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56769304P 2004-05-03 2004-05-03
US60/567,693 2004-05-03
PCT/US2005/014947 WO2005108387A2 (en) 2004-05-03 2005-04-29 Cytokine inhibitors

Publications (3)

Publication Number Publication Date
JP2007536231A JP2007536231A (ja) 2007-12-13
JP2007536231A5 JP2007536231A5 (https=) 2008-06-19
JP4865702B2 true JP4865702B2 (ja) 2012-02-01

Family

ID=35229785

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007511450A Expired - Fee Related JP4865702B2 (ja) 2004-05-03 2005-04-29 サイトカイン阻害剤

Country Status (5)

Country Link
US (3) US7285545B2 (https=)
EP (1) EP1745036A2 (https=)
JP (1) JP4865702B2 (https=)
CA (1) CA2560387C (https=)
WO (1) WO2005108387A2 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
US7531560B2 (en) * 2004-11-10 2009-05-12 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
WO2007056016A2 (en) * 2005-11-02 2007-05-18 Kemia, Inc. Bisamide cytokine inhibitors
CN101365682A (zh) * 2005-12-08 2009-02-11 千禧药品公司 具有激酶抑制活性的双环化合物
US8501749B2 (en) 2009-01-30 2013-08-06 Boehringer Ingelheim International Gmbh Azaquinazolinediones chymase inhibitors
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
HRP20220522T1 (hr) 2014-08-04 2022-06-10 Nuevolution A/S Proizvoljno kondenzirani heterociklil-supstituirani derivati pirimidina koji su korisni za liječenje upalnih, metaboličkih, onkoloških i autoimunih bolesti
EP3365340B1 (en) 2015-10-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170145025A1 (en) 2015-11-19 2017-05-25 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2916874T3 (es) 2015-12-17 2022-07-06 Incyte Corp Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
AU2016379372A1 (en) 2015-12-22 2018-08-02 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
ES2905980T3 (es) 2016-05-26 2022-04-12 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EA202092441A1 (ru) 2016-06-07 2021-05-21 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
BR112018076534A2 (pt) 2016-06-20 2019-04-02 Incyte Corporation compostos heterocíclicos como imunomoduladores
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
ES2941716T3 (es) 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3506906A4 (en) * 2016-08-31 2020-08-12 Taro Pharmaceutical Industries Ltd. TOPICAL FORMULATIONS OF FENOLDOPAM FOR THE TREATMENT OF SKIN DISORDERS
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
EP3558990B1 (en) 2016-12-22 2022-08-10 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
ES2899402T3 (es) 2016-12-22 2022-03-11 Incyte Corp Derivados de piridina como inmunomoduladores
AU2017382870B2 (en) 2016-12-22 2022-03-24 Incyte Corporation Benzooxazole derivatives as immunomodulators
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
KR20240026521A (ko) 2017-03-23 2024-02-28 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
CR20200520A (es) 2018-03-30 2021-03-09 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2019217821A1 (en) 2018-05-11 2019-11-14 Incyte Corporation Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
NZ781774A (en) 2019-03-08 2023-03-31 Taro Pharma Ind Stable topical compositions of fenoldopam
EP4010342A1 (en) 2019-08-09 2022-06-15 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
WO2021067217A1 (en) 2019-09-30 2021-04-08 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
BR112022009031A2 (pt) 2019-11-11 2022-10-11 Incyte Corp Sais e formas cristalinas de um inibidor de pd-1/pd-l1
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
US11685727B2 (en) 2019-12-20 2023-06-27 Nuevolution A/S Compounds active towards nuclear receptors
CA3174176A1 (en) 2020-03-31 2021-10-07 Sanne Schroder Glad Compounds active towards nuclear receptors
EP4126874A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
US11866434B2 (en) 2020-11-06 2024-01-09 Incyte Corporation Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003511442A (ja) * 1999-10-13 2003-03-25 アストラゼネカ アクチボラグ ピリミジン誘導体
WO2003087085A1 (en) * 2002-04-11 2003-10-23 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic amide derivatives as cytokine inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744776A (en) * 1989-07-14 1998-04-28 Tip Engineering Group, Inc. Apparatus and for laser preweakening an automotive trim cover for an air bag deployment opening
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
FR2732967B1 (fr) 1995-04-11 1997-07-04 Sanofi Sa 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
DE19546585A1 (de) * 1995-12-13 1997-06-19 Trw Repa Gmbh Gassack-Abdeckung für ein Fahrzeuginsassen-Rückhaltesystem sowie Verfahren zu deren Herstellung
JP3430841B2 (ja) * 1997-03-05 2003-07-28 豊田合成株式会社 エアバッグカバー
WO1999051580A1 (en) 1998-04-08 1999-10-14 Abbott Laboratories Pyrazole inhibitors of cytokine production
PT1123287E (pt) 1998-10-23 2003-12-31 Dow Agrosciences Llc 1-(piridil substituido)-1,2,4-triazoles insecticidas
US6498423B1 (en) 2001-06-27 2002-12-24 Welch Allyn, Inc. Lamp thermal control by directed air flow
WO2003022820A1 (en) 2001-09-06 2003-03-20 Bristol-Myers Squibb Pharma Company. Heteroaromatic substituted cyclopropane as corticotropin releasing hormone
ES2367422T3 (es) 2001-10-09 2011-11-03 Amgen Inc. Derivados de imidazol como agentes antiinflamatorios.
AU2003209388A1 (en) 2002-01-29 2003-09-02 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
US7078419B2 (en) * 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
DK1618092T3 (da) * 2003-05-01 2011-01-31 Bristol Myers Squibb Co Aryl-substituerede pyrazol-amidforbindelser, der er anvendelige som kinasehæmmere

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003511442A (ja) * 1999-10-13 2003-03-25 アストラゼネカ アクチボラグ ピリミジン誘導体
WO2003087085A1 (en) * 2002-04-11 2003-10-23 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic amide derivatives as cytokine inhibitors

Also Published As

Publication number Publication date
US7592332B2 (en) 2009-09-22
CA2560387C (en) 2013-09-24
WO2005108387A3 (en) 2006-02-16
US7285545B2 (en) 2007-10-23
US20070275946A1 (en) 2007-11-29
EP1745036A2 (en) 2007-01-24
WO2005108387A2 (en) 2005-11-17
JP2007536231A (ja) 2007-12-13
US20050245536A1 (en) 2005-11-03
CA2560387A1 (en) 2005-11-17
US20090023701A1 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
JP4865702B2 (ja) サイトカイン阻害剤
AU2004264409B2 (en) Heterocyclic N-aryl carboxamides as cytokine inhibitors
JP4824576B2 (ja) サイトカイン生成のインヒビターとしての１，２，３−トリアゾールアミド誘導体
JP4578106B2 (ja) サイトカインインヒビターとしてのヘテロ環式アミド誘導体
JP4823218B2 (ja) 抗−サイトカインヘテロ環式化合物
JP4926402B2 (ja) サイトカインインヒビターとしての１，２，３−トリアゾールアミド誘導体
JP5038139B2 (ja) サイトカインインヒビター
EP1867646A1 (en) Cytokine inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110927

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111024

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111110

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141118

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees